United Therapeutics (UTHR) Cost of Revenue (2009 - 2026)

United Therapeutics has disclosed Cost of Revenue across 18 years of filings, most recently posting $133.4 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $133.4 million, up 44.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $425.3 million (up 29.15% YoY), and the FY2025 annual result was $384.4 million, up 24.12% from the prior year.
• Cost of Revenue came in at $133.4 million for Q1 2026 at United Therapeutics, up from $103.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $133.4 million in Q1 2026 to a low of $25.9 million in Q1 2022.
• The 5-year median for Cost of Revenue is $72.9 million (2024), against an average of $72.7 million.
• Across the five-year window, Cost of Revenue slipped 20.16% in 2022 and jumped 115.82% in 2023, its largest moves.
• United Therapeutics' Cost of Revenue stood at $58.8 million in 2022, then rose by 20.75% to $71.0 million in 2023, then advanced by 6.9% to $75.9 million in 2024, then surged by 36.23% to $103.4 million in 2025, then grew by 29.01% to $133.4 million in 2026.
• The last three Cost of Revenue figures came in at $133.4 million (Q1 2026), $103.4 million (Q4 2025), and $100.9 million (Q3 2025), per Business Quant data.